Lilly receives UK approval for pirtobrutinib in relapsed blood cancers
Written by
PharmaTimes
Published
0
comments
0
min
MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma